Literature DB >> 15634022

Design and NMR characterization of active analogues of compstatin containing non-natural amino acids.

Buddhadeb Mallik1, Madan Katragadda, Lynn A Spruce, Caterina Carafides, Christos G Tsokos, Dimitrios Morikis, John D Lambris.   

Abstract

We present new findings in our drug discovery effort to develop an anticomplement therapeutic. We have designed several active analogues of compstatin by altering its amino acid composition at positions 4 and 9. The most effective analogues have tryptophan or fused-ring non-natural amino acids at position 4 and alanine or an unbranched single-methyl amino acid at position 9. Twenty-one of these analogues have 2-99-fold higher activities compared to the parent peptide compstatin. The analogue Ac-V4(2Nal)/H9A-NH(2) has the highest inhibitory activity with IC(50) 500 nM. NMR data, through NOE and chemical shift analysis, suggest the presence of interconverting conformers spanning the extended and helical regions of the Ramachandran plot, and they detect a predominant averaged conformer with coil structure and at least one flexible beta-turn, of type I. The fused-ring non-natural amino acids at position 4 contribute to the formation of the hydrophobic cluster of compstatin, which has been previously proposed, together with the beta-turn and a disulfide bridge, to be essential for binding to the target of compstatin, complement component C3. We propose that additional mechanisms may contribute to the structural stability of the analogues and to binding to C3, involving intra- and intermolecular electrostatic interactions of the pi-electron system of side chain aromatic rings. The presence of pi-pi interactions for Trp4-Trp7 was confirmed with a molecular dynamics simulation for the most active analogue with natural amino acids, Ac-V4W/H9A-NH(2). Alanine or aminobutyric acid at position 9 contribute to the weak propensity for helical structure of the residue segment 4-10 of the analogues, which may also play a role in increased activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15634022     DOI: 10.1021/jm0495531

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  37 in total

1.  In vivo significance of ITK-SLP-76 interaction in cytokine production.

Authors:  Juris A Grasis; David M Guimond; Nicholas R Cam; Krystal Herman; Paola Magotti; John D Lambris; Constantine D Tsoukas
Journal:  Mol Cell Biol       Date:  2010-05-10       Impact factor: 4.272

2.  New compstatin variants through two de novo protein design frameworks.

Authors:  M L Bellows; H K Fung; M S Taylor; C A Floudas; A López de Victoria; D Morikis
Journal:  Biophys J       Date:  2010-05-19       Impact factor: 4.033

3.  A simple, yet highly accurate, QSAR model captures the complement inhibitory activity of compstatin.

Authors:  Chandrika Mulakala; John D Lambris; Yiannis Kaznessis
Journal:  Bioorg Med Chem       Date:  2006-12-13       Impact factor: 3.641

Review 4.  Compstatin: a complement inhibitor on its way to clinical application.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

5.  A new generation of potent complement inhibitors of the Compstatin family.

Authors:  Aliana López de Victoria; Ronald D Gorham; Meghan L Bellows-Peterson; Jun Ling; David D Lo; Christodoulos A Floudas; Dimitrios Morikis
Journal:  Chem Biol Drug Des       Date:  2011-04-26       Impact factor: 2.817

Review 6.  Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.

Authors:  Daniel Ricklin; Edimara S Reis; Dimitrios C Mastellos; Piet Gros; John D Lambris
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

7.  Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis.

Authors:  Harald F Langer; Kyoung-Jin Chung; Valeria V Orlova; Eun Young Choi; Sunil Kaul; Michael J Kruhlak; Markella Alatsatianos; Robert A DeAngelis; Paul A Roche; Paola Magotti; Xuri Li; Matina Economopoulou; Stavros Rafail; John D Lambris; Triantafyllos Chavakis
Journal:  Blood       Date:  2010-07-12       Impact factor: 22.113

8.  Rational design of cell-permeable cyclic peptides containing a d-Pro-l-Pro motif.

Authors:  Jin Wen; Hui Liao; Kye Stachowski; Jordan P Hempfling; Ziqing Qian; Chunhua Yuan; Mark P Foster; Dehua Pei
Journal:  Bioorg Med Chem       Date:  2020-08-18       Impact factor: 3.641

9.  Discovery of a Branched Peptide That Recognizes the Rev Response Element (RRE) RNA and Blocks HIV-1 Replication.

Authors:  Yumin Dai; Jessica E Wynn; Ashley N Peralta; Chringma Sherpa; Bhargavi Jayaraman; Hao Li; Astha Verma; Alan D Frankel; Stuart F Le Grice; Webster L Santos
Journal:  J Med Chem       Date:  2018-10-18       Impact factor: 7.446

10.  Cell membrane modification for rapid display of bi-functional peptides: a novel approach to reduce complement activation.

Authors:  Ledia Goga; Gustavo Perez-Abadia; Sathnur B Pushpakumar; Daniel Cramer; Jun Yan; Nathan Todnem; Gary Anderson; Chirag Soni; John Barker; Claudio Maldonado
Journal:  Open Cardiovasc Med J       Date:  2010-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.